NAMS Menopause Certification Exam
2026/2027 | Newly Released| Latest Update
100 Questions with Verified Answers & Rationales
Graded A+| 100% Correct | Guaranteed Pass
Q1: A 34-year-old woman presents with secondary amenorrhea for 4 months, hot flashes, and
night sweats. Her serum FSH is 45 IU/L and estradiol is 15 pg/mL. She is interested in fertility.
What is the most appropriate counseling regarding her reproductive potential?
A. Spontaneous pregnancy is impossible, and she should pursue adoption immediately.
B. She has a 5-10% chance of spontaneous ovulation and pregnancy, and contraception is
needed if she wishes to avoid pregnancy.
C. Pregnancy is guaranteed if she starts hormone therapy.
D. Her fertility is unaffected by these hormone levels.
Correct Answer: B
Rationale: Correct because women with Premature Ovarian Insufficiency (POI) experience
intermittent and unpredictable ovarian function in approximately 5-10% of cases, meaning
spontaneous pregnancy is possible. NAMS guidelines advise that contraception should be used if
pregnancy is not desired, despite the diagnosis of POI.
Q2: Which of the following hormones is the earliest and most reliable marker of diminishing
ovarian reserve during the reproductive years?
A. Follicle Stimulating Hormone (FSH)
B. Estradiol
C. Inhibin B
D. Anti-Müllerian Hormone (AMH)
Correct Answer: D
Rationale: Correct because AMH is produced solely by small antral follicles and declines
steadily as the ovarian follicle pool diminishes, unlike FSH which rises only later in the
transition. AMH remains relatively constant across the menstrual cycle, making it a reliable
early marker of ovarian aging before menstrual irregularity begins.
Q3: A 58-year-old woman with a history of deep vein thrombosis (DVT) suffers from severe
dyspareunia due to atrophic vaginitis. Over-the-counter lubricants have failed. What is the most
appropriate next step?
A. Oral estrogen therapy
B. Transdermal estrogen therapy
C. Vaginal estrogen therapy (ring, tablet, or cream)
D. Systemic progesterone therapy
Correct Answer: C
,Rationale: Correct because low-dose vaginal estrogen results in minimal systemic absorption,
generally keeping serum estradiol levels within the postmenopausal range and posing a
negligible risk for VTE recurrence. Current NAMS guidance supports the use of vaginal estrogen
in women with a history of VTE after shared decision-making.
Q4: [Case Study] A 49-year-old woman presents with 4 months of menstrual cycles occurring
every 21 days. She reports occasional night sweats. She has no contraindications to hormones.
Which of the following best describes her stage according to the STRAW+10 system?
A. Late Reproductive Stage (Stage -3)
B. Early Menopausal Transition (Stage -2)
C. Late Menopausal Transition (Stage -1)
D. Early Postmenopause (Stage +1)
Correct Answer: B
Rationale: Correct because the Early Menopausal Transition (Stage -2) is defined by a
persistent difference in consecutive cycle lengths of 7 days or more. A shortening of the cycle to
21 days in a previously regular woman meets this criterion of increased variability.
Q5: Which of the following is a contraindication to the use of combination estrogen-progestogen
therapy (EPT)?
A. Hypertriglyceridemia
B. Active liver disease or hepatic adenoma
C. Migraine headaches without aura
D. Family history of breast cancer
Correct Answer: B
Rationale: Correct because active liver disease and hepatic adenomas are absolute
contraindications to the use of oral estrogens due to the first-pass hepatic metabolism and the
risk of hepatic rupture or worsening liver function. Migraine without aura and family history of
breast cancer require caution but are not absolute contraindications.
Q6: A 52-year-old woman asks about the impact of menopause on her cardiovascular health.
What lipid changes are most characteristic of the menopause transition?
A. Decrease in LDL cholesterol and increase in HDL cholesterol
B. Increase in LDL cholesterol and decrease in HDL cholesterol
C. Increase in HDL cholesterol only
D. No change in lipid profile
Correct Answer: B
Rationale: Correct because the decline in endogenous estrogen during menopause is
associated with an unfavorable lipid profile, specifically an increase in low-density lipoprotein
(LDL) cholesterol and lipoprotein(a), and a decrease in high-density lipoprotein (HDL)
cholesterol. These changes contribute to the increased cardiovascular risk observed in
postmenopausal women.
, Q7: Which non-hormonal pharmacologic agent is most appropriate for a woman with a history
of breast cancer who is experiencing debilitating hot flashes and cannot take SSRIs due to
interactions with tamoxifen?
A. Paroxetine
B. Fluoxetine
C. Gabapentin
D. Estrogen patch
Correct Answer: C
Rationale: Correct because gabapentin is an effective non-hormonal treatment for vasomotor
symptoms that does not interact with tamoxifen metabolism. Paroxetine and fluoxetine are
strong CYP2D6 inhibitors that can reduce the efficacy of tamoxifen, making them less desirable
choices in this specific population.
Q8: [Case Study] A 65-year-old woman with a T-score of -3.0 at the hip and a history of
vertebral fracture is unable to tolerate oral bisphosphonates due to severe GERD. Which
medication is the most appropriate alternative?
A. Raloxifene
B. Teriparatide
C. Denosumab
D. Calcitonin
Correct Answer: C
Rationale: Correct because denosumab is a subcutaneous injection that bypasses the
gastrointestinal tract, eliminating the risk of esophageal irritation associated with oral
bisphosphonates. It is a potent antiresorptive agent indicated for the treatment of osteoporosis
in high-risk patients.
Q9: A 51-year-old woman on oral estrogen therapy complains of nausea and breast tenderness.
What is the best management strategy?
A. Increase the progestogen dose
B. Switch from oral to transdermal estrogen
C. Discontinue therapy immediately
D. Add an antiemetic
Correct Answer: B
Rationale: Correct because transdermal estrogen avoids first-pass hepatic metabolism,
resulting in lower hepatic estrogen concentrations and a reduced risk of nausea and breast
tenderness compared to oral administration. This route conversion often alleviates dose-
dependent side effects while maintaining efficacy.
2026/2027 | Newly Released| Latest Update
100 Questions with Verified Answers & Rationales
Graded A+| 100% Correct | Guaranteed Pass
Q1: A 34-year-old woman presents with secondary amenorrhea for 4 months, hot flashes, and
night sweats. Her serum FSH is 45 IU/L and estradiol is 15 pg/mL. She is interested in fertility.
What is the most appropriate counseling regarding her reproductive potential?
A. Spontaneous pregnancy is impossible, and she should pursue adoption immediately.
B. She has a 5-10% chance of spontaneous ovulation and pregnancy, and contraception is
needed if she wishes to avoid pregnancy.
C. Pregnancy is guaranteed if she starts hormone therapy.
D. Her fertility is unaffected by these hormone levels.
Correct Answer: B
Rationale: Correct because women with Premature Ovarian Insufficiency (POI) experience
intermittent and unpredictable ovarian function in approximately 5-10% of cases, meaning
spontaneous pregnancy is possible. NAMS guidelines advise that contraception should be used if
pregnancy is not desired, despite the diagnosis of POI.
Q2: Which of the following hormones is the earliest and most reliable marker of diminishing
ovarian reserve during the reproductive years?
A. Follicle Stimulating Hormone (FSH)
B. Estradiol
C. Inhibin B
D. Anti-Müllerian Hormone (AMH)
Correct Answer: D
Rationale: Correct because AMH is produced solely by small antral follicles and declines
steadily as the ovarian follicle pool diminishes, unlike FSH which rises only later in the
transition. AMH remains relatively constant across the menstrual cycle, making it a reliable
early marker of ovarian aging before menstrual irregularity begins.
Q3: A 58-year-old woman with a history of deep vein thrombosis (DVT) suffers from severe
dyspareunia due to atrophic vaginitis. Over-the-counter lubricants have failed. What is the most
appropriate next step?
A. Oral estrogen therapy
B. Transdermal estrogen therapy
C. Vaginal estrogen therapy (ring, tablet, or cream)
D. Systemic progesterone therapy
Correct Answer: C
,Rationale: Correct because low-dose vaginal estrogen results in minimal systemic absorption,
generally keeping serum estradiol levels within the postmenopausal range and posing a
negligible risk for VTE recurrence. Current NAMS guidance supports the use of vaginal estrogen
in women with a history of VTE after shared decision-making.
Q4: [Case Study] A 49-year-old woman presents with 4 months of menstrual cycles occurring
every 21 days. She reports occasional night sweats. She has no contraindications to hormones.
Which of the following best describes her stage according to the STRAW+10 system?
A. Late Reproductive Stage (Stage -3)
B. Early Menopausal Transition (Stage -2)
C. Late Menopausal Transition (Stage -1)
D. Early Postmenopause (Stage +1)
Correct Answer: B
Rationale: Correct because the Early Menopausal Transition (Stage -2) is defined by a
persistent difference in consecutive cycle lengths of 7 days or more. A shortening of the cycle to
21 days in a previously regular woman meets this criterion of increased variability.
Q5: Which of the following is a contraindication to the use of combination estrogen-progestogen
therapy (EPT)?
A. Hypertriglyceridemia
B. Active liver disease or hepatic adenoma
C. Migraine headaches without aura
D. Family history of breast cancer
Correct Answer: B
Rationale: Correct because active liver disease and hepatic adenomas are absolute
contraindications to the use of oral estrogens due to the first-pass hepatic metabolism and the
risk of hepatic rupture or worsening liver function. Migraine without aura and family history of
breast cancer require caution but are not absolute contraindications.
Q6: A 52-year-old woman asks about the impact of menopause on her cardiovascular health.
What lipid changes are most characteristic of the menopause transition?
A. Decrease in LDL cholesterol and increase in HDL cholesterol
B. Increase in LDL cholesterol and decrease in HDL cholesterol
C. Increase in HDL cholesterol only
D. No change in lipid profile
Correct Answer: B
Rationale: Correct because the decline in endogenous estrogen during menopause is
associated with an unfavorable lipid profile, specifically an increase in low-density lipoprotein
(LDL) cholesterol and lipoprotein(a), and a decrease in high-density lipoprotein (HDL)
cholesterol. These changes contribute to the increased cardiovascular risk observed in
postmenopausal women.
, Q7: Which non-hormonal pharmacologic agent is most appropriate for a woman with a history
of breast cancer who is experiencing debilitating hot flashes and cannot take SSRIs due to
interactions with tamoxifen?
A. Paroxetine
B. Fluoxetine
C. Gabapentin
D. Estrogen patch
Correct Answer: C
Rationale: Correct because gabapentin is an effective non-hormonal treatment for vasomotor
symptoms that does not interact with tamoxifen metabolism. Paroxetine and fluoxetine are
strong CYP2D6 inhibitors that can reduce the efficacy of tamoxifen, making them less desirable
choices in this specific population.
Q8: [Case Study] A 65-year-old woman with a T-score of -3.0 at the hip and a history of
vertebral fracture is unable to tolerate oral bisphosphonates due to severe GERD. Which
medication is the most appropriate alternative?
A. Raloxifene
B. Teriparatide
C. Denosumab
D. Calcitonin
Correct Answer: C
Rationale: Correct because denosumab is a subcutaneous injection that bypasses the
gastrointestinal tract, eliminating the risk of esophageal irritation associated with oral
bisphosphonates. It is a potent antiresorptive agent indicated for the treatment of osteoporosis
in high-risk patients.
Q9: A 51-year-old woman on oral estrogen therapy complains of nausea and breast tenderness.
What is the best management strategy?
A. Increase the progestogen dose
B. Switch from oral to transdermal estrogen
C. Discontinue therapy immediately
D. Add an antiemetic
Correct Answer: B
Rationale: Correct because transdermal estrogen avoids first-pass hepatic metabolism,
resulting in lower hepatic estrogen concentrations and a reduced risk of nausea and breast
tenderness compared to oral administration. This route conversion often alleviates dose-
dependent side effects while maintaining efficacy.
